FY2025 EPS Estimate for Gilead Sciences Boosted by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Gilead Sciences in a report issued on Wednesday, February 19th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will post earnings of $7.98 per share for the year, up from their prior forecast of $7.24. Cantor Fitzgerald currently has a “Neutral” rating and a $80.00 price target on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

A number of other analysts also recently commented on the company. Oppenheimer boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Citigroup started coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Robert W. Baird boosted their target price on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Finally, Barclays boosted their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $102.08.

Gilead Sciences Stock Down 0.1 %

GILD opened at $109.95 on Friday. The business’s fifty day moving average is $95.41 and its two-hundred day moving average is $88.73. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market cap of $137.03 billion, a price-to-earnings ratio of 297.16, a PEG ratio of 0.71 and a beta of 0.18. Gilead Sciences has a one year low of $62.07 and a one year high of $111.03.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in GILD. HHM Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the period. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences in the third quarter worth about $25,000. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $29,000. Finally, Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the sale, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $17,597,559.49. This represents a 1.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 713,000 shares of company stock worth $67,945,181. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 832.43%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.